The study of transgenic and gene-deleted (knockout) mice provides important insights into the in vivo function and interaction of specific gene products. Within the pharmaceutical industry, genetically altered mice are used predominantly in discovery research to characterize the diverse functions of one or multiple gene products or to establish animal models of human disease for proof-ofconcept studies. We recently used genetically altered animals in drug discovery to examine the NF-KB family of transcriptional regulatory genes and to elucidate their essential role in the early onset of immune and inflammatory responses. Transgenic and knockout mice are also useful in drug development, because questions regarding risk assessment and carcinogenesis, xenobiotic metabolism, receptor-and ligand-mediated toxicity, and immunotoxicity can be evaluated using these genetically altered mice. For example, the p53 knockout mouse is one of several genetically altered mice whose use may increase the sensitivity and decrease the time and cost of rodent carcinogenicity bioassays. As with any experimental model system, data obtained from genetically altered mice must be interpreted carefully. The complete inactivation of a gene may result in altered expression of related genes or physiologic compensation for the loss of the gene product. Consideration must also be given to the genetic background of the mouse strain and the impact of strain variability on disease or toxicity models. Despite these potential limitations, knockout mice provide a powerful tool for the advancement of drugs in the pharmaceutical industry.
INTRODUCTION
The utilization of genetically altered animals has become commonplace within the pharmaceutical industry. Sophisticated technical advances have created an unprecedented opportunity for investigators to determine the function and interaction of specific gene products in an experimental animal system. Numerous animal species have been successfully genetically altered (2, 9, 24) . For both technical and nontechnical reasons, the most common genetically altered animal species used in the pharmaceutical industry are mice. Genetically altered mice are used in discovery research to characterize the diverse functions of one or multiple gene products or to establish animal models of human disease for proof-of-concept studies. Genetically altered mice are used in risk assessment for genotoxicity and carcinogenicity screening and for the mechanistic evaluation of drug-induced pathology and toxicology. The purpose of drug discovery studies is the validation of a therapeutic target for intervention, and the goal of risk assessment studies is to elucidate the liabilities associated with a drug candidate.
TRANSGENIC AND GENE-KNOCKOUT MICE
The rate of progress in transgenic science has been remarkable; <25 yr has passed since Janenisch and Mintz first demonstrated that foreign DNA could be introduced into fertilized mouse eggs and then detected in various tissues of the transgenic mice that developed from these embryos (28) . Shortly thereafter, these same investigators demonstrated that murine retroviral sequences could be stably integrated into the embryonal genome and transmitted as a Mendelian trait to offspring (25, 27) . Retroviral transduction has promising applications in human somatic cell therapy, but this technique has been less useful in the generation of transgenic animals. Direct DNA injection into the pronucleus of fertilized 1-cell eggs is now the gold standard for the generation of transgenic mice (21; for review see 12, 26) . Transgenic mice usually overexpress the inserted gene, resulting in a &dquo;gain of function.&dquo; In some cases, the transgene is designed so that the gene product interferes with the wild-type gene product, a dominant negative effect that results in &dquo;loss of function.&dquo; Despite the efficiency and consistency of pronuclear microinjection to create transgenic animals, major hurdles exist, including the inability to control sites of DNA integration and copy numbers of the transgenes. Random integration and multiple transgene copy numbers lead to unregulated expression both temporally and spatially, sometimes resulting in aberrant phenotypes in the transgenic animal (45) .
The lack of specificity in transgene integration has largely been circumvented by the development of homologous recombination-based gene-targeting techniques (for review see 8, 48, 49) . These techniques require the use of the pluripotential embryonic stem cell, which has only been isolated from the mouse (16) . Gene targeting in the mouse results in the inactivation, alteration, or substitution of a specific gene (1, 42) . When the gene is inactivated the mouse is commonly referred to as a knockout. Knockout mice are used to elucidate the function of a gene of interest, especially with regard to its role in fetal development and organogenesis. An unexpected phenotype in a gene knockout mice can also provide clues to the pathogenesis of important diseases. Pharmacologic manipulation of knockout mice has provided significant experimental models for screening potential therapeutic agents.
LIMITATIONS AND RECENT ADVANCES IN

TRANSGENIC TECHNOLOGY
Despite remarkable advances in transgenic and knockout mouse technology, several considerations are important for the evaluation of the transgenic or knockout mouse phenotype. The insertion location and copy number of transgenes is variable in transgenic mice and can alter transgene or wild-type gene expression and complicate phenotype evaluation (5, 8, 20, 42) . Redundant functions of gene products may alter or mask the phenotype of a transgenic or knockout mouse (42, 50) . In knockout mice, the gene deletion may be crucial for development, and embryonic lethality may preclude further evaluation of the gene product in adult knockout mice (6, 11, 42) . During development or disease there may be physiologic compensation for the loss of a gene product in the knockout mouse (37) . The genetic background of mice may influence the transgenic or knockout phenotype, especially in animal models of human disease (23, 35, 44) .
Recent advances in transgenic and gene-targeting technologies have expanded the utility of genetically manipulated animals (for review see 42). These modifications will enable researchers to manipulate the transgenic animal or knockout mouse so that the above limitations may be circumvented. To control the location or time of transgene expression, transgene promoters are used to target the expression of a transgene to a specific tissue or period of organogenesis or are engineered to contain tetracycline-, estrogen-, or ecdysome-inducible elements such that gene expression is exogenously controlled (7, 36, 39, 42, 43, 45) . The Cre recombinase/lox P system (4, 22, 41) can be used to alter the copy number of transgenes, thereby providing better control of transgene expression (20) . To avoid lethal deletions in knockout mice or physiologic compensation by a different gene product, genes can now be deleted selectively in certain tissues or deleted conditionally at a specific time in development using variations of the Cre recombinase/loxP system (4, 17, 22, 29, 39, 45, 46) .
USE OF GENETICALLY ALTERED MICE IN DRUG DISCOVERY
Transgenic and knockout mouse models are extremely useful in drug discovery, especially when defining potential therapeutic targets for modifying immune and inflammatory responses. We recently used genetically altered animals to examine the NF-KB family of transcriptional regulatory genes and elucidated their essential role in the early onset of immune and inflammatory responses. Rel/ NF-KB transcription factors contain a highly conserved region, the Rel homology domain, that is responsible for DNA binding and dimerization. In mammalian cells, this protein family can be divided into 2 classes based upon precursor synthesis and proteolytic processing. NF-KB exists in an inactive form in the cytoplasm and is associated with the inhibitory IKB molecules. Summaries of the corresponding phenotypes resulting from overexpression or inactivation of this gene family has been recently published (3) . All of the classic limitations for working with transgenic and knockout mice have been observed with this gene family, including embryonal lethality (6) , genetic redundancy (50) , physiologic compensation (37) , and influence of strain variability on the phenotype (unpublished observations).
USE OF GENETICALLY ALTERED MICE IN RISK ASSESSMENT
Transgenic animal and knockout mouse models also have utility in risk assessment and are being evaluated for applications in drug development. Specific areas for which these animal models may be useful are in screening for drug-induced immunotoxicity (31, 40) , genotoxicity (32, 34) , and carcinogenicity (10, 15, 39, 47, 51) and in understanding toxicity related to drug-metabolizing enzyme systems (19, 35) . Rodent carcinogenicity bioassays involve lengthy and costly studies that are limited in their sensitivity by the lifespan and background tumor load of the rodent (10, 33) . Since 1995, the International Life Sciences Institute and over 45 laboratories and pharmaceutical companies have been evaluating several transgenic model systems for assessing the carcinogenicity of pharmaceuticals (38) . Similar studies are being undertaken by the National Institute of Environmental Health Sciences for environmental toxins and chemical carcinogens (15) . Genetically manipulated strains being studied include CB6F1-Tg-Hras2 (10, 51) and Tg.AC (10, 47) transgenic mice and P53 heterozygote (10, 13, 47) and XPA (13) knockout mice. These transgenic and knockout mouse strains have an increased susceptibility to tumorigenesis caused by various genotoxic and nongenotoxic carcinogens and ultraviolet radiation (13, 15, 47, 51) . A   TABLE I. -Internet Web site addresses for products and services related to transgenics. bioassay using these genetically manipulated mice could provide a more timely and sensitive tool for evaluating the carcinogenic effects of drug compounds.
There are other research areas where transgenic and gene knockout technology may be useful in risk assessment. Genetically altered mice are useful for determining mechanisms of toxicity and their applicability to humans. Notable examples include the PPARa knockout (mechanisms of hepatocellular peroxisome proliferation) (30) , Ah receptor knockout (mechanism of dioxin immunotoxicity) (18) , and an extensive series of cytokine or cytokine receptor knockouts (40) . Mice with genetically altered phase 1 metabolism (e.g., CYP450 enzyme transgenics/knockouts) or phase 2 metabolism (e.g., glutathione and glucuronyl transferase transgenics/knockouts) will further define the relationship between drug toxicity and drug metabolism, an important focus in risk assessment (19, 35) . Transgenic and gene knockout mice can be used to study diverse manifestations of toxicity, such as drug-mediated overproduction of cytokines, stimulation of the acute phase response, induction of myelosuppression, and altered regulation of apoptosis (40) .
THE FUTURE
The discovery and risk assessment of pharmaceutical compounds will continue to benefit from the advancements of transgenic and gene-targeting technology. The techniques of genetic engineering will modify and improve genetically manipulated animal models. The commercial availability of transgenic and knockout founder strains will continue to increase (Table I) , and researchers with specific mutant strains will collaborate with private industry. Pathologists will be important in developing the appropriate uses and evaluation of these mutant strains and will be instrumental in their successful application to drug development issues. These animal models are exciting and revealing and will make a significant impact in the pharmaceutical industry for years to come.
